Citius Oncology, Inc. (CTOR) - Uzoq muddatli qarzning kapitalga nisbati
Citius Oncology, Inc. (CTOR) ishlab chiqarish va sinov ishlarini uchinchi tomon pudratchilariga topshiradi va o'z zavodlarini biznes modelidan butunlay chiqarib tashlaydi. Shu bilan birga, sinov protokollarining qat'iy nazorati dori vositalarining barqaror ishlab chiqilishini ta'minlaydi. Quyidagi grafikdagi narxlar tarixi aktivning dinamikasini aks ettiradi, bunda ko'rsatkich 0.26 darajasida turibdi. Biznesning muvaffaqiyati AQSh tartibga soluvchi organlarining tasdig'iga, analoglarga nisbatan terapevtik ustunlikka va sug'urta kompaniyalarining davolash xarajatlarini qoplashga bo'lgan tayyorgarligiga asoslangan.
%20Uzoq%20muddatli%20qarzning%20o'z%20kapitaliga%20nisbati&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_CTOR_-_Citius-Oncology-Inc._-_Long-Term-Debt-to-Equity "citiusonc.com (CTOR): Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi 14.08.2024dan 31.10.2026gacha | 👁️GURU.Markets👁️")
Citius Oncology, Inc. kompaniyasining tahliliy kesimlari
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- kompaniyaning balans qiymati tafsilotlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Citius Oncology, Inc.|CTOR - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati citiusonc.com|CTOR - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Citius Oncology, Inc.|CTOR - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Citius Oncology|Tezkor likvidlik koeffitsiyenti citiusonc.com
- moliyaviy natijalar va qiymat multiplikatorlari tafsilotlari:
Kompaniyaning umumiy tahlili:Citius Oncology Inc. - CTOR
Ushbu ko'rsatkich tashqi moliyalashtirishga bog'liqlik darajasini aniqlash uchun bir yildan ortiq muddatli majburiyatlarni umumiy kapital bilan solishtirish orqali moliyaviy barqarorlikni baholaydi. Uzoq muddatli qarzlarning kapitalga nisbati tahlili Citius Oncology, Inc. (CTOR) uchun juda muhimdir, chunki savdo yo'qligidagi yuqori xarajatlar sur'ati va dori vositalarini sertifikatlashtirishning murakkabligi kompaniyani qarz yuklamasiga nisbatan o'ta zaif qiladi.
Muhim raqobatchilar
Uzoq muddatli qarzning o'z kapitaliga nisbati BeiGene Ltd. (ONC)|Uzoq muddatli qarzning kapitalga nisbati HALO|Uzoq muddatli qarzning kapitalga nisbati Revolution Medicines Corp (RVMD)|Uzoq muddatli qarzning o'z kapitaliga nisbati Ascentage Pharma Group AAPG|CGON: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|UroGen Pharma - Uzoq muddatli qarzning kapitalga nisbati|Bicara Therapeutics Inc (BCAX) - Uzoq muddatli qarzning o'z kapitaliga nisbati|PSNL: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Erasca Oncology (ERAS)|Uzoq muddatli qarzning o'z kapitaliga nisbati Delcath Systems, Inc.|YMAB: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati AURA (Aura Biosciences)|CADL (candeltx.com) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati ARAY (Accuray Inc.)|SLS - Uzoq muddatli qarzning o'z kapitaliga nisbati|ACTU: Uzoq muddatli qarzning o'z kapitaliga nisbati|HURA - Uzoq muddatli qarzning kapitalga nisbati|Protara Therapeutics, Inc. (TARA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Fate Therapeutics Inc - Uzoq muddatli qarzning kapitalga koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati TScan TCRX|Uzoq muddatli qarzning kapitalga nisbati CSBR|Uzoq muddatli qarzning o'z kapitaliga nisbati xbiotech.com XBIT|Uzoq muddatli qarzning kapitalga nisbati CVM (CEL-SCI)|Uzoq muddatli qarzdorlikning kapitalga nisbati OS Therapies Inc. (OSTX)|RADX: Uzoq muddatli qarzning o'z kapitaliga nisbati|Artiva Biotherapeutics, Inc. - Uzoq muddatli kreditlarning kapitalga nisbati|ANL: Uzoq muddatli qarzning kapitalga nisbati|VERU - Uzoq muddatli qarzdorlikning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati TPST|Uzoq muddatli qarzning kapitalga nisbati Xilio|Uzoq muddatli qarzning o'z kapitaliga nisbati Renovaro Inc. (RENB)|Uzoq muddatli qarzdorlikning kapitalga nisbati muraloncology.com|Kairos Pharma - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti OKUR|GDTC - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Curis, Inc.|apollomicsinc.com (APLM) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi THAR|ADVB (Advanced Biomed Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati genprex.com (GNPX)|Uzoq muddatli qarzning o'z kapitaliga nisbati Calidi Biotherapeutics (CLDI)|SBFM - Uzoq muddatli majburiyatlarning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Xenetic Biosciences, Inc. XBIO|Salarius Pharma - Uzoq muddatli qarzning o'z kapitaliga nisbati|PPBT - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati American Oncology Network|BGNE: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati Checkpoint Therapeutics Inc. CKPT|Uzoq muddatli qarzning o'z kapitaliga nisbati ELEV|Uzoq muddatli majburiyatlarning kapitalga nisbati iCAD Corp ICAD|Uzoq muddatli qarzning o'z kapitaliga nisbati IKNA (Ikena Oncology, Inc.)|NTBL (notablelabs.com) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati VIRX (Viracta Therapeutics, Inc.)|Uzoq muddatli qarzdorlikning kapitalga nisbati MorphoSys Inc (MOR)|NAYA - Uzoq muddatli qarzning o'z kapitaliga nisbati|AAPGV (Ascentage) - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi